Skandinaviska Enskilda Banken (SEB)’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$9.1M Sell
72,390
-70,371
-49% -$8.84M 0.04% 307
2025
Q1
$15.8M Sell
142,761
-37,645
-21% -$4.16M 0.08% 209
2024
Q4
$24.7M Sell
180,406
-123,436
-41% -$16.9M 0.11% 151
2024
Q3
$35M Buy
303,842
+184,005
+154% +$21.2M 0.16% 112
2024
Q2
$16.5M Buy
119,837
+2,877
+2% +$396K 0.08% 196
2024
Q1
$16.1M Buy
116,960
+54,419
+87% +$7.51M 0.08% 209
2023
Q4
$8.24M Buy
62,541
+22,559
+56% +$2.97M 0.05% 290
2023
Q3
$4.5M Sell
39,982
-86,335
-68% -$9.71M 0.03% 377
2023
Q2
$11.9M Sell
126,317
-58,378
-32% -$5.51M 0.08% 232
2023
Q1
$18.7M Buy
184,695
+29,574
+19% +$2.99M 0.13% 171
2022
Q4
$18.5M Sell
155,121
-1,663
-1% -$199K 0.14% 164
2022
Q3
$16.7M Buy
156,784
+4,233
+3% +$450K 0.13% 155
2022
Q2
$14.9M Sell
152,551
-2,702
-2% -$263K 0.11% 186
2022
Q1
$14.6M Buy
155,253
+1,633
+1% +$153K 0.09% 212
2021
Q4
$13M Sell
153,620
-114
-0.1% -$9.65K 0.07% 245
2021
Q3
$14.7M Sell
153,734
-380
-0.2% -$36.4K 0.08% 231
2021
Q2
$15M Buy
154,114
+16,585
+12% +$1.61M 0.09% 214
2021
Q1
$13.4M Buy
137,529
+81,715
+146% +$7.95M 0.09% 223
2020
Q4
$5.35M Sell
55,814
-356
-0.6% -$34.1K 0.04% 352
2020
Q3
$5.4M Buy
56,170
+10,770
+24% +$1.04M 0.04% 322
2020
Q2
$5.54M Buy
45,400
+6,000
+15% +$732K 0.04% 308
2020
Q1
$3.41M Sell
39,400
-13,900
-26% -$1.2M 0.03% 355
2019
Q4
$5.73M Buy
53,300
+5,900
+12% +$634K 0.05% 300
2019
Q3
$4.27M Sell
47,400
-8,000
-14% -$721K 0.04% 350
2019
Q2
$4.68M Buy
+55,400
New +$4.68M 0.04% 322